Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Phillips

Interventional Pain Medicine Eugene, OR Medical Doctor

NPI 1033319124 CMS profile 137993

74B Centennial Loop Ste 300, Neurospine Institute LLC, Eugene, OR 97401

Open in the dashboard

General payments

$49,666

522 records reported · program years 2019–2025

Research payments

$6,138

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,035,702 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Gregory Phillips of Eugene, OR is reported in the CMS Open Payments database as having received $49,666 across 522 general payments and $6,138 in research payments paid to them. Separately, studies naming them as principal investigator received $2,035,702 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,043 49
2024 General $18,667 116
2023 General $3,736 113
2022 General $7,265 93
2021 General $9,042 57
2021 Research $4,888 2
2020 General $3,437 46
2019 General $4,476 48
2019 Research $1,250 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Phillips
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Gregory Phillips were reported at $3,043. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Gregory Phillips Interventional Pain Medicine median Middle half National median
2019 $4,476 $684 $216–$2,079 $163
2020 $3,437 $382 $122–$1,109 $114
2021 $9,042 $552 $167–$1,554 $132
2022 $7,265 $605 $187–$1,924 $149
2023 $3,736 $671 $195–$1,915 $160
2024 $18,667 $684 $206–$1,837 $164
2025 $3,043 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $9,451 84 payments
  2. Vertos Medical, Inc. $8,692 16 payments
  3. Boston Scientific Corporation $7,576 111 payments
  4. Biotronik Inc. $4,800 3 payments
  5. Painteq LLC $3,861 26 payments
  6. Vertiflex, Inc. $3,684 15 payments
  7. Abbott Laboratories $2,451 130 payments
  8. MML US, Inc. $2,149 14 payments
  9. BIOTRONIK NRO, Inc. $1,928 8 payments
  10. Saluda Medical Americas, Inc. $1,711 10 payments
  11. Other $3,363 105 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,529 478 payments
  2. Travel and Lodging $12,820 30 payments
  3. Consulting Fee $10,503 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,125 3 payments
  5. Education $1,689 6 payments
Products named General payments · program years 2019–2025
  1. mild Device Kit $8,692 16 payments
  2. INTELLIS ADAPTIVESTIM $7,042 47 payments
  3. Superion $5,017 3 payments
  4. PAINTEQ $3,861 26 payments
  5. Superion ISS $3,684 15 payments
  6. ReActiv8 $2,149 14 payments
  7. OSTEOCOOL RF ABLATION SYSTEM $2,034 13 payments
  8. Prospera $1,905 7 payments
  9. Evoke $1,697 9 payments
  10. Nalu Neurostimulation System $1,068 44 payments
  11. Other $8,754 341 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Boston Scientific Corporation $4,888 2 payments
  2. Flowonix Medical Incorporated $1,250 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

282

Median for Interventional Pain Management: 1,220

Drug cost

$10,405

Median for Interventional Pain Management: $39,344

Branded share of claims

37.2%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 13 $4,483
Oxycontin Oxycodone Hcl Brand 11 $2,689
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 54 $680
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 27 $588
Oxycodone Hcl Generic 55 $557
Gabapentin Generic 38 $548
Buprenorphine Hcl Generic 11 $254
Trazodone Hcl Generic 14 $224
Ondansetron Hcl Generic 13 $180
Pregabalin Generic 12 $109

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$150,105

Of which drugs: $3,602

Medicare patients

342

Average age 74

Services billed

4,549

209 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Depression 31%
Chronic kidney disease 26%
Diabetes 23%
Ischemic heart disease 20%
Osteoporosis 20%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 47 2,255 $235
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 125 $98

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $130
$130 — —
JARDIANCE
  • Lilly USA, LLC $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

525 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record